NCT01537185已完成1 期
A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 2
- 主要终点
- Unsolicited Adverse Event Reports
研究概览
简要总结
The purpose of this study is to determine if a Streptococcus pneumoniae Whole Cell Vaccine (SPWCV) given with alum is safe and well tolerated by healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Currently consumes alcohol in excess of 2 drinks per day for men or 1 drink per day for women.
- •current use or likely requirement for medications with potential for liver injury or effect immune system
- •History of event or condition such as anaphylaxis, severe allergic reactions, serious reactions to any vaccines, or other events that might increase risk of reaction to an investigational disease
- •History of diabetes, cancer, autoimmune or immunosuppressive disease or chronic such as HIV, Hepatitis B or C
结局指标
主要结局
Unsolicited Adverse Event Reports
时间窗: within 1 week (0-7 days) following each vaccinations
Safety and Tolerability assessed by cohort and product received measured by: •Number of unsolicited AEs within four weeks after each vaccination
次要结局
- Immunogenicity Determined by the Number of Subjects With >4x Increase in Anti IgG(28, 56 and 84 days following initial vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)Pneumococcal InfectionsNCT01513551Merck Sharp & Dohme LLC692
已完成
1 期
Phase 1b Influenza Vaccine Study in Healthy SubjectsInfluenzaNCT01181336PepTcell Limited48
已完成
1 期
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsPneumococcal DiseaseNCT06182124Pfizer1,363
招募中
1 期
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerTriple Negative Breast CancerHER2-negative Breast CancerNCT05504707H. Lee Moffitt Cancer Center and Research Institute30
已完成
1 期
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of AgeStreptococcal InfectionsNCT01193920Novartis Vaccines380